Study guide

8.1 Ethical Eligibility, Recruitment and Retention

ACRP CCRA Certified Clinical Research Associate Study Guide 2026 Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Format, Eligibility and Registration

1.1 Exam Format, Eligibility and Current References 1.2 Registration, Fees and Candidate Decisions

2 Chapter 2: CRA Responsibilities and Study Planning

2.1 The CRA Role, Data Integrity and Product Oversight 2.2 Official Blueprint and Study Strategy

3 Chapter 3: Protocols, Endpoints and Trial Design

3.1 Protocol Elements and Endpoint Hierarchy 3.2 Endpoint Interpretation and Eligibility Rationale 3.3 Eligibility Verification and Trial Designs

4 Chapter 4: Bias Control, Blinding and Product Information

4.1 Bias, Randomisation and Comparator Controls 4.2 Unblinding and Investigator Brochure Content 4.3 Reference Safety Information and IB Updates

5 Chapter 5: Estimands and Device Instructions

5.1 Estimands and Intercurrent Events 5.2 Device Instructions, Configuration and Training

6 Chapter 6: Ethical Foundations and Independent Oversight

6.1 Ethical Foundations and the 2024 Declaration of Helsinki 6.2 Vulnerability, Voluntariness and Compensation 6.3 IRB/IEC Composition and Independent Review

7 Chapter 7: Ethics Communication and Informed Consent

7.1 Ethics Reporting, Approval Status and Version Control 7.2 Informed Consent Information and Meaningful Choice 7.3 Consent Documentation, Special Circumstances and Updates

8 Chapter 8: Recruitment, Retention and Confidentiality

8.1 Ethical Eligibility, Recruitment and Retention 8.2 Privacy, Confidentiality and Appropriate Access

9 Chapter 9: Safety Definitions and Classification

9.1 Adverse Event Definitions and Actual Life-Threatening Risk 9.2 Seriousness, Severity and Medical Importance 9.3 Causality, Expectedness and Reference Safety Information

10 Chapter 10: Safety Detection, Reporting and Oversight

10.1 Detecting Events, AESIs and Collection Windows 10.2 Expedited Reporting and the Sponsor Awareness Clock 10.3 Immediate Site Reporting and Independent Safety Oversight

11 Chapter 11: Follow-Up, Adherence and Conflicts

11.1 Safety Communications, Reconciliation and Follow-Up 11.2 Adherence, Discontinuation and Participant Choice 11.3 Conflicts of Interest and Prorated Payments

12 Chapter 12: Development Stages and Product Management

12.1 Nonclinical Background and Human Pharmacology 12.2 Exploratory, Confirmatory and Therapeutic-Use Studies 12.3 Product Storage, Labelling and Excursion Response

13 Chapter 13: Accountability, Integrity and Regulatory Status

13.1 Product Accountability and Adherence Calculations 13.2 Potential Fraud, Misconduct and Evidence Preservation 13.3 Submissions, Authorisation Status and Trial Reporting

14 Chapter 14: Current GCP Principles and Delegation

14.1 The Eleven Current GCP Principles 14.2 Proportionality and Investigator Oversight 14.3 Delegation, Qualifications and Task Authority

15 Chapter 15: Oversight, Protocol Control and Amendments

15.1 Clinical Oversight and Immediate-Hazard Changes 15.2 Deviation Classification and Resolution

16 Chapter 16: Implementation and Trial Responsibilities

16.1 Amendment Implementation and Communication 16.2 Sponsor, Investigator and Service-Provider Roles

17 Chapter 17: Quality Planning, Root Causes and CAPA

17.1 Quality Planning and Risk Management 17.2 Root Cause Analysis and CAPA Design 17.3 CAPA Implementation and Effectiveness Verification

18 Chapter 18: Risk Assessment and Monitoring Methods

18.1 Risk Assessment and Centralised Surveillance 18.2 Monitoring Methods and Source Review

19 Chapter 19: Quality Metrics, Plans and Communication

19.1 KRIs, Acceptable Ranges and Trial-Level Quality 19.2 Monitoring Plans, Co-Monitoring and Communication

20 Chapter 20: Site Qualification and Readiness

20.1 Site Qualification and Investigator Capacity 20.2 Recruitment Feasibility and Evidence-Based Site Selection 20.3 Site Readiness and Activity-Specific Release

21 Chapter 21: Initiation, Equipment and Supplies

21.1 Initiation Training and Readiness Walkthroughs 21.2 Equipment, Maintenance and Study Supplies

22 Chapter 22: Samples, Diagnostics and Financial Feasibility

22.1 Specimens, Diagnostic Results and Rater Quality 22.2 Contracts, Budgets and Operational Feasibility

23 Chapter 23: Interim Monitoring and Reporting

23.1 Interim Visit Preparation and Consent Review 23.2 Monitoring Eligibility, Safety and Products 23.3 Investigator Debrief and Monitoring Reports

24 Chapter 24: Essential Records, Audits and Findings

24.1 Essential Records and Site/Sponsor Reconciliation 24.2 Version History, Resolution Evidence and Noncompliance 24.3 Audits, Inspections and Closure Planning

25 Chapter 25: Close-Out, Retention and Destruction

25.1 Close-Out, Archiving and Continuing Obligations 25.2 Retention, Destruction and Long-Term Access

26 Chapter 26: Source Records and Good Documentation

26.1 Source Records and Foundational ALCOA Principles 26.2 Good Documentation, Completeness and Corrections 26.3 Source Access, Certified Copies and Context

27 Chapter 27: Electronic Systems, Metadata and Queries

27.1 EDC Design and Fit-for-Purpose Systems 27.2 Audit Trails, Electronic Outcomes and Device Choice 27.3 Queries, Coding and Supported Clinical Meaning

28 Chapter 28: Dataset Finalisation and Critical Data

28.1 Safety Reconciliation and Dataset Finalisation 28.2 Critical Data, Acquisition Tools and Interim Findings

8.1 Ethical Eligibility, Recruitment and Retention

Key Takeaways Explain This Topic AI

Recruitment materials and methods should match the ethics-reviewed process.

Retention efforts must respect freedom to withdraw without penalty.

Recruitment and dropout metrics require contextual investigation rather than automatic conclusions.

Last updated: October 2026

Ethical Eligibility, Recruitment and Retention

Eligibility criteria serve scientific and safety purposes. The ethics committee evaluates the proposed population together with the protocol, consent, recruitment process and safeguards. A monitor should understand why a criterion exists, verify it from appropriate evidence and recognise when the site's recruitment practice undermines its purpose. Good recruitment reaches suitable people fairly; it does not relax criteria to improve site metrics.

A criterion may reduce a known risk, define the condition under study, support a reliable measurement or limit a confounding treatment. Distinguish these rationales from habitual exclusions that unnecessarily reduce representativeness. E6(R3) and the 2024 Declaration of Helsinki encourage appropriate representation and attention to the harms of exclusion. However, revising an unjustified restriction requires the authorised protocol/amendment process, not an individual monitor's waiver.

Examining an eligibility decision

Trace diagnosis, relevant history, laboratory or imaging evidence, timing, prohibited treatments and required investigator review. A checked box saying eligible is not enough when the supporting result is absent. Also distinguish a result obtained after enrolment from a result available before enrolment but filed later. The clinical and data consequences can differ, even though both situations need accurate records.

If evidence suggests an ineligible participant was enrolled, promptly involve the investigator and sponsor. The investigator evaluates care and the protocol's continuation/discontinuation rules; the sponsor assesses wider implications and reporting. The CRA documents the finding and follow-up without prescribing treatment or offering a retrospective exception. Do not infer that every eligibility error automatically removes all the participant's data from analysis.

Recruitment materials and methods

Review advertisements, referral scripts, social-media messages and participant-facing explanations as applicable. Compare actual material with the approved version and the process described to the IRB/IEC. Look for promises of cure, guaranteed benefit, misleading claims about payment, omission of meaningful burdens or pressure from a treating clinician. The recruitment process should make the research nature clear while allowing understandable, balanced information.

Recruitment issue Why it matters Monitoring response

An obsolete advertisement promises a benefit absent from the current protocol Potential misunderstanding and undue influence Verify actual use, notify responsible staff and correct through the approved process

Staff pre-screen an unrelated patient list without appropriate access Confidentiality risk Establish permitted access and stop inappropriate use through the responsible functions

The site uses one language although its population needs others Unfair access and poor comprehension Assess translation/interpreter planning and approved materials

Completion payment dominates the message Pressure to remain despite concerns Check ethics-reviewed amount, method and schedule

An accessible process can include suitable languages, understandable materials, reasonable scheduling and removal of unnecessary financial barriers. The same safeguards should reach remote participants, not only people visiting the clinic. A digital recruitment platform introduces access and privacy questions; outsourcing recruitment does not remove sponsor or investigator oversight.

Retention without pressure

Retention protects interpretability and can reduce missing data, but participants remain free to withdraw. Ask why people miss visits or stop participating: travel burden, treatment effects, inflexible scheduling, confusing instructions, technology problems or dissatisfaction with communication. Reasonable improvements may help, provided they remain within the protocol and reviewed process. For example, arranging an authorised visit option may be appropriate; inventing an unapproved home procedure is not.

Contact should be respectful and consistent with permission. Do not threaten loss of ordinary medical care, withhold earned prorated payment or repeatedly contact someone who has declined further contact. A participant need not provide a reason for withdrawal. Document what they choose and what follow-up, if any, they allow. Explain options without implying that continued research is required for care.

Interpreting recruitment and dropout metrics

An unusually high conversion rate can signal pre-screening methods, a genuinely suitable referral population, missing screen failures or improper enrolment. A high dropout rate can reflect disease progression, burden or site problems. Review denominators, eligibility complexity, exposure and data completeness before concluding misconduct or poor care. Metrics guide investigation rather than prove a cause.

For an illustrative feasibility estimate, a site sees 100 potentially relevant patients in a period. If 40 meet detailed criteria and half of those are realistically willing and able to participate, the estimated recruitment opportunity is 20, before considering competing trials and time limits. The arithmetic is 100 × 0.40 × 0.50 = 20. These are stated hypothetical inputs, not published CCRA benchmarks. The CRA should ask for the evidence supporting each assumption.

Track planned versus actual enrolment and reasons for nonparticipation while protecting privacy. Feed supported findings back into feasibility, participant communication and quality review. Successful recruitment means appropriate, voluntary participation with reliable follow-up, not simply a large randomisation total.

Official sources

Checked October 18, 2026: ICH E6(R3), Principles and Annex 1 , WMA Declaration of Helsinki, 2024 , ICH E11(R1) .